Sientra shares are trading higher the company announced FDA clearance for its AlloX2 Pro Tissue Expander.
Portfolio Pulse from Benzinga Newsdesk
Sientra announced FDA clearance for its AlloX2 Pro Tissue Expander, leading to a rise in its share prices.
June 09, 2023 | 2:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sientra's shares are trading higher after the company received FDA clearance for its AlloX2 Pro Tissue Expander.
The FDA clearance for Sientra's AlloX2 Pro Tissue Expander is a significant milestone for the company, as it allows them to market and sell the product in the US. This is likely to lead to increased revenues and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100